Shots:

• Mammoth Biosciences to receive $40M up front, research funding & target option exercise fees, $1B+ upon achievement of research, development & commercial milestones for 5 preselected in vivo indications for liver-targeted diseases & is eligible to receive royalties. Both companies also investigate ex vivo projects on a nonexclusive basis
• The agreement bolsters Bayer’s new cell & gene therapy platform by using Mammoth’s CRISPR systems to develop in vivo gene-editing therapies
• Additionally, Bayer gains access to Mammoth Biosciences’ gene-editing technology that offers the potential of an advanced in vivo applicability due to the ultra-compact size of novel CRISPR systems

Ref: Businesswire | Image: Businesswire